Overview of the biosimilars: Strategic considerations of various issues

Journal of Generic Medicines

Volumn 9, Issue 4, 2012, Pages 187-206

  Kudrin, Alex ^a  

^a Takeda Pharmaceutical Company   (United Kingdom)

Author keywords

Biosimilar; Extrapolation; Immunogenicity; Market access; Pipeline

Indexed keywords

ABCIXIMAB; ADALIMUMAB; ALEMTUZUMAB; ALPHA INTERFERON; ANTINEOPLASTIC AGENT; AZATHIOPRINE; BIOLOGICAL PRODUCT; BIOSIMILAR AGENT; CETUXIMAB; CLOTINAB; DENOSUMAB; DISEASE MODIFYING ANTIRHEUMATIC DRUG; ERYTHROPOIETIN; ETANERCEPT; GENERIC DRUG; GRANULOCYTE COLONY STIMULATING FACTOR; GROWTH HORMONE; HUMAN GROWTH HORMONE; INFLIXIMAB; INTERFERON; METHOTREXATE; MONOCLONAL ANTIBODY; OMALIZUMAB; PALIVIZUMAB; RECOMBINANT ERYTHROPOIETIN; RECOMBINANT GRANULOCYTE COLONY STIMULATING FACTOR; RITUXIMAB; STEROID; TRASTUZUMAB; TUMOR NECROSIS FACTOR INHIBITOR; UNCLASSIFIED DRUG; UNINDEXED DRUG; YI BI AO; YI SAI PU;

AUTOIMMUNE DISEASE; BIOEQUIVALENCE; BREAST CANCER; CHRONIC LYMPHATIC LEUKEMIA; COST CONTROL; CROHN DISEASE; DRUG APPROVAL; DRUG DOSAGE FORM COMPARISON; DRUG EFFICACY; DRUG INDICATION; DRUG INDUSTRY; DRUG MARKETING; DRUG MECHANISM; DRUG QUALITY; DRUG RESEARCH; DRUG SAFETY; DRUG STRUCTURE; DRUG SURVEILLANCE PROGRAM; FOLLICULAR LYMPHOMA; HUMAN; IMMUNOGENICITY; MALIGNANT NEOPLASTIC DISEASE; NONHUMAN; PATENT; PATIENT; REVIEW; RHEUMATOID ARTHRITIS; VIRUS INFECTION;

EID: 84877881506     PISSN: 17411343     EISSN: 17417090     Source Type: Journal    
DOI: 10.1177/1741134312470444     Document Type: Review

References (30)

1. IMS. The global use of medicines: Outlook Through 2016, July 2012.
2. Datamonitor. Biosimilars: Market entry strategies. Report no. HC00149-003, December 2011.
3. SCRIP Business Insights. Strategies for entering the biosimilars market. Report no. BI00050-010, December 2011.
4. Woollett GR. Progress report on biosimilars from the world's largest biologics market - the US. Generics & Biosimilars Conference, Barcelona, January 2012.
5. Miller S and Houts J. Potential savings of biogenerics in the United States. Express Scripts, http://www.expressscripts.com/industryresearch/ outcomes/onlinepublications/study/potentialSavingsBiogenericsUS.pdf (2007, accessed 13 August 2012).
6. Ward M. Biosimilars move to centre stage, http://www.scripintelligence. com/home/comment/Biosimilars-move-to-centre-stage-305148 (2010, accessed 13 August 2012).
7. Arnum PV. Opportunities in the biosimilars market. Pharmaceut Technol 2010; 34: 1-10.
8. Cassinotti A and Travis S. Incidence and clinical significance of immunogenicity to infliximab in Crohn's disease: A critical systematic review. Inflamm Bowel Dis 2009; 15: 1264-1275.
9. D'Haens G, Baert F, van Assche G, et al. Belgian Inflammatory Bowel Disease Research Group; North-Holland Gut Club. Early combined immunosuppression or conventional management in patients with newly diagnosed Crohn's disease: an open randomised trial. Lancet 2008; 371: 660-667.
10. Colombel JF, Rutgeerts P, Reinisch W, et al. SONIC: a randomized, double blind, controlled trial comparing infliximab and infliximab plus azathioprine to azathioprine in patients with Crohn's disease naïve to immunomodulators and biologic therapy. Gut 2008; 57(Suppl II): A1.
11. Feagan B, MacDonald JWD, Panaccione R, et al. A randomized, placebo-controlled study to evaluate the efficacy of infliximab in combination with methotrexate for the long-term treatment of Crohn's disease. Gastroenterology 2008; 134(4 Suppl 1): Abstract 682C.
12. Goekoop-Rueterman YPM, Vries-Bouwstra JK, Allart CF, et al. Clinical and radiographic outcomes of four different treatment strategies in patients with early rheumatoid arthritis (the BeSt study): A randomized, controlled trial. Arthritis Rheumat 2005; 52: 3381-3390.
13. Buch MH, Smolen JS, Betteridge N, et al. Updated consenus statement on the use of rituximab in patients with rheumatoid arthritis. Ann Rheum Dis 2011; 70: 909-920.
14. Beukelman T, Patkar NM, Saag KG, et al. American College of Rheumatology Recommendations for the treatment of juvenile idiopathic arthritis: Initiation and safety monitoring of therapeutic agents for the treatment of arthritis and systemic features. Arthritis Care Res 2011; 63: 465-482.
15. Dignass A, Van Assche G, Lindsay JO, et al. The second European evidence-based consensus on the diagnosis and management of Crohn's disease: Current management. J Crohn's Colitis 2010; 4: 28-62.
16. National Comprehensive Cancer Network. Guidelines on treatment on non-Hodgkin lymphoma, http://www.nccn.org/professionals/physician-gls/f- guidelinesasp (2012, accessed 13 August 2012).
17. WHO. Guidelines on Evaluation of Similar Biotherapeutic Products (SBPs). WHO/BS/09.2110, http://www.who.int/biologicals/publications/trs/areas/ biological-therapeutics/BS2110Dft-guidelines-Final-HK-IK-29July-09.pdf (2009, accessed 13 August 2012).
18. PMDA. Guideline for the quality, safety and effectiveness of biosimilar products (in Japanese), www.pmda.go.jp (2009, accessed on 13 August 2012).
19. FDA. Draft Guidance for industry on scientific considerations in demonstrating biosimilarity to a reference product (issued jointly by CDER and CBER, February 2012), http://www.fda.gov/Drugs/DevelopmentApprovalProcess/ HowDrugsareDevelopedandApproved/ApprovalApplications/ TherapeuticBiologicApplications/Biosimilars/default.htm (2012, accessed 13 August 2012).
20. Sherman RE. Biosimilar biological products, http://www.fda.gov/downloads/ Drugs/DevelopmentApprovalProcess/HowDrugsareDevelopedandApproved/ ApprovalApplications/TherapeuticBiologicApplications/Biosimilars/UCM292463.pdf (2012, accessed 13 August 2012).
21. Berkowitz SA, Engen JR, Mazzeo JR, et al. Analytical tools for characterizing biopharmaceuticals and the implications for biosimilars. Nature Rev Drug Disc 2012; 11: 527-540.
22. EMA. Tysabri: Summary of Product Characteristics, http://www.ema.europa. eu/docs/en-GB/document-library/EPAR-Product-Information/human/000603/ WC500044686.pdf (2012, accessed 13 August 2012).
23. Citiline. Drug development overview: Biosimilar monoclonal antibodies, http://www.citeline.com/wp-content/uploads/Drug-Development-Overview-Biosimilar- Monoclonal-Antibodies-16-May-2012.pdf (2012, accessed 13 August 2012).
24. Celltrion. KFDA approves Remsima, www.celltrion.com (2012, accessed 13 August 2012).
25. Shaw BE, Confer DL, Hwang WY, et al. Concerns about the use of biosimilar granulocyte colony-stimulating factors for the mobilization of stem cells in normal donors: position of the World Marrow Donor Association. Haematologica 2011; 96: 942-947.
26. Praditpornsilpa K, Tiranathanagul K, Kupatawintu P, et al. Biosimilar recombinant human erythropoietin induces the production of neutralizing antibodies. Kidney Int 2011; 80: 88-92.
27. Clinicaltrial.gov. A prospective, immunogenicity surveillance registry of erythropoiesis stimulating agent (ESA) with subcutaneous exposure in Thailand, http://www.clinicaltrial.gov/ct2/show/NCT00799019?term=NCT00799019&rank=1 (2012, accessed 13 August 2012).
28. Kermani F. The German Biosimilars Breakthrough that Never Was, http://invivoblog.blogspot.com/2011/10/german-biosimilars-breakthrough-that. html (2011, accessed 13 August 2012).
29. EGA. 8th EGA Annual International Symposium On Biosimilar Medicines, http://www.egagenerics.com/bio-articles.htm (2010, accessed 13 August 2012).
30. Bruce F. Scottish HTA recommends generic filgrastim despite 'Weakness' of better efficacy, http://www.scripintelligence.com/policyregulation/Scottish- HTA-recommends-generic-filgrastim-despite-weakness-ofbetter-efficacy-310423 (2011, accessed 13 August 2012).